Sofinnova Investments, a Menlo Park, CA-based clinical stage biopharmaceutical investment firm, promoted Maha Katabi, PhD, CFA to General Partner and Sarah Bhagat, PhD to Partner.
Maha Katabi, PhD, CFA who joined Sofinnova in April 2019, has been essential to the firm’s executive team in addition to enhancing the team’s geographic investment coverage across North America and Europe. She is an experienced investor in biopharma companies, with more than two decades of venture capital and public equities investment experience. Katabi was a Partner at Sectoral Asset Management since 2008, where she formed and led a dedicated investment team and advisory board to drive investments in private life science companies.
Prior to joining Sofinnova, Katabi co-invested with Sofinnova in multiple companies, including Apellis Pharmaceuticals (APLS), Ascendis Pharma (ASND), and Trius Therapeutics (acquired by Cubist). She recently led Sofinnova’s investment in Northsea Therapeutics and serves as a Board of Director. Sarah Bhagat, PhD who joined Sofinnova in April 2017, has made significant investment and organizational contributions to the firm. Bhagat has been pivotal to making and helping manage numerous investments at Sofinnova, including Aeovian, Apellis (APLS), Neurana, NextCure (NXTC) NorthSea, Pionyr, and YmAbs (YMAB). She led Sofinnova’s investments in Inozyme, Promedior, and Akouos. She implemented and manages Sofinnova’s Fellowship Program, which is aimed at providing entrepreneurial and investing experience to Stanford graduate and medical students. Bhagat is on the board of Stanford’s Neuroscience Translate Oversight Committee. Prior to joining Sofinnova, she was a postdoctoral fellow at Stanford University. She was also a Venture Fellow for Canaan Partners.
Founded in 1974, Sofinnova is a clinical-stage biopharmaceutical investment firm with approximately $2.3B in assets under management and committed capital.